Insite Vision Inc (INSV) 0.3475 $INSV QLT Termi
Post# of 273249
Posted On: 07/26/2016 6:13:25 PM
Insite Vision Inc (INSV) 0.3475 $INSV
QLT Terminates $20 Million Private Placement
GlobeNewswire - Mon May 02, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that it has terminated the previously announced US$20 million private placement in QLT. The Company's Board of Directors (the "Board" has determined that it would not be in the best interests of QLT to dilute its existing shareholders.
QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
Global Blepharitis Pipeline Review, H1 2016 Featuring Allergan, InSite Vision, Kala Pharma, NicOx & Senju Pharma - Research and Markets
BusinessWire - Wed Apr 13, 5:57AM CDT
Research and Markets has announced the addition of the "Blepharitis - Pipeline Review, H1 2016" report to their offering.
AGN: 248.95 (+1.10)
Cataract - Pipeline Review - Companies Mentioned Include EyeGate Pharmaceuticals, InSite Vision Incorporated, Laboratories Sophia S.A. de C.V., Omeros Corporation & R-Tech Ueno - Research and Markets
BusinessWire - Fri Jan 29, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/4t3ppk/cataract) has announced the addition of the "Cataract - Pipeline Review, H2 2015" report to their offering.
OMER: 10.97 (+0.02)
Cataract - Pipeline Review - Companies Mentioned Include EyeGate Pharmaceuticals, InSite Vision Incorporated, Laboratories Sophia S.A. de C.V., Omeros Corporation & R-Tech Ueno
M2 - Fri Jan 29, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bvgpjg/cataract) has announced the addition of the "Cataract - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataracts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Omeros Corporation - R-Tech Ueno, Ltd. Key Topics Covered: - Introduction - Cataract Overview - Therapeutics Development - Pipeline Products for Cataract - Overview - Pipeline Products for Cataract - Comparative Analysis - Cataract- Therapeutics under Development by Companies - Cataract- Therapeutics under Investigation by Universities/Institutes - Cataract- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cataract- Products under Development by Companies - Cataract- Products under Investigation by Universities/Institutes - Cataract- Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/bvgpjg/cataract
EYEG: 2.41 (+0.01), OMER: 10.97 (+0.02)
World Bacterial Conjunctivitis Pipeline Review, H2 2015
M2 - Wed Jan 06, 8:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6tpk3/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - List of Tables - List of Figures - Introduction - Bacterial Conjunctivitis Overview - Therapeutics Development - Pipeline Products for Bacterial Conjunctivitis - Overview - Bacterial Conjunctivitis - Therapeutics under Development by Companies - Bacterial Conjunctivitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bacterial Conjunctivitis - Products under Development by Companies - Bacterial Conjunctivitis - Companies Involved in Therapeutics Development - Cellceutix Corporation - China Grand Wuhan General Pharmaceutical Research Institute - Daiichi Sankyo Company, Limited - InSite Vision Incorporated - NovaBay Pharmaceuticals, Inc. - Ocular Therapeutix, Inc. - Senju Pharmaceutical Co., Ltd. - Shire Plc For more information visit http://www.researchandmarkets.com/research/k6tpk3/bacterial
SHPG: 193.60 (+1.31), OCUL: 4.64 (+0.22)
Ocular Pain - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/jstqvz/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H2 2015" report to their offering. The report Ocular Pain - Pipeline Review, H2 2015', provides an overview of the Ocular Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Ocular Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ocular Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ocular Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Ocular Therapeutix, Inc. - Reata Pharmaceuticals, Inc. - Sylentis S.A. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/js...cular_pain
VRX.TO: 30.37 (+0.15), OCUL: 4.64 (+0.22)
Global Antibacterial Drugs Market 2015-2019
M2 - Fri Dec 04, 4:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/nm7f8c/global) has announced the addition of the "Global Antibacterial Drugs Market 2015-2019" report to their offering. The report forecasts the global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019. The report presents scenario and growth prospects of the global antibacterial drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global antibacterial drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Antibacterial Overview PART 06: Pipeline analysis PART 07: Antimicrobial resistance PART 08: Legislation relating to antibiotic use in the US PART 09: Market landscape PART 10: Market segmentation by chemical class PART 11: Market segmentation by drug origin PART 12: Market segmentation by mechanism of action PART 13: Market segmentation by spectrum of activity PART 14: Geographical segmentation PART 15: Market drivers PART 16: Impact of drivers PART 17: Market challenges PART 18: Impact of drivers and challenges PART 19: Market trends PART 20: Vendor landscape PART 21: Key vendor analysis - Allergan - GSK - Merck - Pfizer - Sandoz - Teva Pharmaceuticals - Abbott - Achaogen - Actelion - AmpliPhi Biosciences - Aspen Pharmacare - Astellas - AstraZeneca - Aurobindo Pharma - Baxter - Basilea Pharmaceuticals - Bayer - Biocon - Bristol-Myers Squibb - Cempra - Cipher Pharmaceuticals - Corden Pharma - Cornerstone Therapeutics - Eli Lilly - Exoxemis - F.Hoffmann-La Roche - Flynn Pharma - Hospira - Incepta Pharmaceuticals - InSite Vision - Insmed Incorporated - Johnson & Johnson - KaloBios Pharmaceuticals - Kyorin Pharmaceutical - Lupin Pharmaceuticals - Lytix Biopharma - Melinta Therapeutics - Mylan - Nektar - Orchid Pharma - Par Pharmaceutical - Paratek Pharmaceuticals - Pernix Therapeutics - PTC Therapeutics - RedHill Biopharma - Sagent Pharmaceuticals - Sanofi - Shionogi - Starpharma - Sun Pharmaceutical - Symbiomix - Takeda Pharma - Tetraphase Pharmaceuticals - Theravance Biopharma - The Medicines Company - Valneva - Wockhardt. For more information visit http://www.researchandmarkets.com/research/nm7f8c/global
TTPH: 4.16 (unch), INSM: 10.93 (-0.14), RDHL: 12.46 (+0.16), LLY: 82.09 (+0.11), BMY: 75.06 (-0.50), PRTK: 12.97 (-0.03), APHB: 1.46 (-0.04), AGN: 248.95 (+1.10), JNJ: 125.15 (+0.26), MRK: 58.36 (-0.20), SGNT: 21.64 (-0.03), PTCT: 5.88 (-0.88), TBPH: 22.84 (+0.25)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 94.98 (-0.79), RIGL: 2.27 (+0.03), OCUL: 4.64 (+0.22), AGN: 248.95 (+1.10), SHPG: 193.60 (+1.31), MRK: 58.36 (-0.20), CLTX: 36.01 (+16.34)
InSite Vision announces unsolicited acquisition proposal from buyer at USD0.25 per share in cash
M2 - Sun Nov 08, 3:01AM CST
InSite Vision (OtherOTC:INSV) said on Monday that it has received an unsolicited proposal for the acquisition of all outstanding shares of its common stock at a price of USD0.25 per share in cash.
QLT (QLTI) Reports Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 11:15AM CDT
QLT Inc. (QLTI) reported a third-quarter 2015 loss of 5 cents per share.
QLTI: 1.38 (-0.02), AMAG: 24.95 (-0.76), ANIK: 51.83 (+0.02)
Ocular (OCUL) Initiates Third Phase III Study on Dextenza
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:25PM CDT
Ocular (OCUL) initiated patient enrolment in the third phase III study on Dextenza for the treatment of post-surgical ocular inflammation and pain.
AGN: 248.95 (+1.10), OCUL: 4.64 (+0.22), NVS: 83.02 (-0.44)
InSite Vision Terminates QLT Deal in Favor of Sun Pharma
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 3:50PM CDT
InSite Vision Inc. (INSV) announced that it has terminated its agreement with QLT Inc. (QLTI).
QLTI: 1.38 (-0.02), GILD: 81.05 (-7.50), REGN: 398.27 (+3.37)
InSite Vision enters into merger agreement with Sun Pharma at USD0.35 per share
M2 - Wed Sep 16, 5:41AM CDT
Ophthalmologic company InSite Vision (OtherOTC:INSV) revealed on Tuesday the launch of a merger agreement with a subsidiary of Sun Pharmaceutical Industries through a tender offer.
QLT Announces Termination of Merger Agreement With InSite Vision
GlobeNewswire - Tue Sep 15, 5:16PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" today announced that its agreement to acquire InSite Vision Incorporated (OTCBB:INSV) ("InSite" has been terminated.
QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
InSite Vision and Sun Pharma Enter into Merger Agreement
BusinessWire - Tue Sep 15, 3:23PM CDT
--InSite Terminates Merger Agreement with QLT Inc.
QLTI: 1.38 (-0.02)
Eye Infections Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/376x9w/eye_infections) has announced the addition of the "Eye Infections Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report provides an overview of Eye Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Eye Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Alcon - Allergan - Dompe Farmaceutici - InSite Vision - Laboratoires Thea - Merck & Co. - Novartis - SIFI - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/37...infections
AGN: 248.95 (+1.10), MRK: 58.36 (-0.20), VRX.TO: 30.37 (+0.15), NVS: 83.02 (-0.44)
Is Another Amendment of QLT-InSite Vision Deal Coming Up?
Zacks Equity Research - Zacks Investment Research - Tue Sep 08, 3:25PM CDT
InSite Vision Inc. (INSV), which is set to be acquired by QLT Inc. (QLTI), announced that it has received a superior unsolicited offer from a global pharmaceutical company.
QLTI: 1.38 (-0.02), GILD: 81.05 (-7.50), REGN: 398.27 (+3.37)
QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Fri Sep 04, 8:01PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite" that the board of directors of InSite has determined, in good faith and after consultation with its independent financial and legal advisors, that the second unsolicited offer, as announced in QLT's press release on September 3, 2015, from the multi-national pharmaceutical company (the "Bidder" to acquire all of the issued and outstanding shares of InSite (the "New Proposal" constitutes a "Company Superior Proposal", as defined in the Amended and Restated Agreement and Plan of Merger, dated June 8, 2015, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated on July 16, 2015 and August 26, 2015 (the "Amended and Restated Merger Agreement" .
QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a "Company Superior Proposal"
BusinessWire - Fri Sep 04, 4:49PM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that InSite's Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company (the "Bidder" to acquire all outstanding shares of InSite Vision common stock at $0.35 per share in an all-cash transaction constitutes a "Company Superior Proposal" as defined in InSite's previously announced definitive agreement with QLT Inc. dated as of August 26, 2015 (NASDAQ:QLTI) (TSX:QLT).
QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Thu Sep 03, 5:35PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite" that InSite has received a second unsolicited offer from the multi-national pharmaceutical company which initially made an unsolicited offer, as announced in QLT's press release on August 10, 2015, to acquire all of the issued and outstanding shares of InSite (the "New Proposal" . The New Proposal is only subject to due diligence regarding the recently filed BromSite patent lawsuit. InSite has further advised QLT that the board of directors of InSite, in consultation with its financial and legal advisors, will carefully review all aspects of the New Proposal, and has not changed its recommendation with respect to the proposed merger with QLT pursuant to the Amended and Restated Agreement and Plan of Merger, dated June 8, 2015, by and among InSite, QLT and Isotope Acquisition Corp., as amended and restated on July 16, 2015 and August 26, 2015 (the "Amended and Restated Merger Agreement" . The Amended and Restated Merger Agreement continues in full force and effect.
QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
QLT Terminates $20 Million Private Placement
GlobeNewswire - Mon May 02, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that it has terminated the previously announced US$20 million private placement in QLT. The Company's Board of Directors (the "Board" has determined that it would not be in the best interests of QLT to dilute its existing shareholders. QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
Global Blepharitis Pipeline Review, H1 2016 Featuring Allergan, InSite Vision, Kala Pharma, NicOx & Senju Pharma - Research and Markets
BusinessWire - Wed Apr 13, 5:57AM CDT
Research and Markets has announced the addition of the "Blepharitis - Pipeline Review, H1 2016" report to their offering.
AGN: 248.95 (+1.10)
Cataract - Pipeline Review - Companies Mentioned Include EyeGate Pharmaceuticals, InSite Vision Incorporated, Laboratories Sophia S.A. de C.V., Omeros Corporation & R-Tech Ueno - Research and Markets
BusinessWire - Fri Jan 29, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/4t3ppk/cataract) has announced the addition of the "Cataract - Pipeline Review, H2 2015" report to their offering.
OMER: 10.97 (+0.02)
Cataract - Pipeline Review - Companies Mentioned Include EyeGate Pharmaceuticals, InSite Vision Incorporated, Laboratories Sophia S.A. de C.V., Omeros Corporation & R-Tech Ueno
M2 - Fri Jan 29, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bvgpjg/cataract) has announced the addition of the "Cataract - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataracts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Omeros Corporation - R-Tech Ueno, Ltd. Key Topics Covered: - Introduction - Cataract Overview - Therapeutics Development - Pipeline Products for Cataract - Overview - Pipeline Products for Cataract - Comparative Analysis - Cataract- Therapeutics under Development by Companies - Cataract- Therapeutics under Investigation by Universities/Institutes - Cataract- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cataract- Products under Development by Companies - Cataract- Products under Investigation by Universities/Institutes - Cataract- Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/bvgpjg/cataract
EYEG: 2.41 (+0.01), OMER: 10.97 (+0.02)
World Bacterial Conjunctivitis Pipeline Review, H2 2015
M2 - Wed Jan 06, 8:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6tpk3/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - List of Tables - List of Figures - Introduction - Bacterial Conjunctivitis Overview - Therapeutics Development - Pipeline Products for Bacterial Conjunctivitis - Overview - Bacterial Conjunctivitis - Therapeutics under Development by Companies - Bacterial Conjunctivitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bacterial Conjunctivitis - Products under Development by Companies - Bacterial Conjunctivitis - Companies Involved in Therapeutics Development - Cellceutix Corporation - China Grand Wuhan General Pharmaceutical Research Institute - Daiichi Sankyo Company, Limited - InSite Vision Incorporated - NovaBay Pharmaceuticals, Inc. - Ocular Therapeutix, Inc. - Senju Pharmaceutical Co., Ltd. - Shire Plc For more information visit http://www.researchandmarkets.com/research/k6tpk3/bacterial
SHPG: 193.60 (+1.31), OCUL: 4.64 (+0.22)
Ocular Pain - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/jstqvz/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H2 2015" report to their offering. The report Ocular Pain - Pipeline Review, H2 2015', provides an overview of the Ocular Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Ocular Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ocular Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ocular Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Ocular Therapeutix, Inc. - Reata Pharmaceuticals, Inc. - Sylentis S.A. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/js...cular_pain
VRX.TO: 30.37 (+0.15), OCUL: 4.64 (+0.22)
Global Antibacterial Drugs Market 2015-2019
M2 - Fri Dec 04, 4:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/nm7f8c/global) has announced the addition of the "Global Antibacterial Drugs Market 2015-2019" report to their offering. The report forecasts the global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019. The report presents scenario and growth prospects of the global antibacterial drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global antibacterial drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Antibacterial Overview PART 06: Pipeline analysis PART 07: Antimicrobial resistance PART 08: Legislation relating to antibiotic use in the US PART 09: Market landscape PART 10: Market segmentation by chemical class PART 11: Market segmentation by drug origin PART 12: Market segmentation by mechanism of action PART 13: Market segmentation by spectrum of activity PART 14: Geographical segmentation PART 15: Market drivers PART 16: Impact of drivers PART 17: Market challenges PART 18: Impact of drivers and challenges PART 19: Market trends PART 20: Vendor landscape PART 21: Key vendor analysis - Allergan - GSK - Merck - Pfizer - Sandoz - Teva Pharmaceuticals - Abbott - Achaogen - Actelion - AmpliPhi Biosciences - Aspen Pharmacare - Astellas - AstraZeneca - Aurobindo Pharma - Baxter - Basilea Pharmaceuticals - Bayer - Biocon - Bristol-Myers Squibb - Cempra - Cipher Pharmaceuticals - Corden Pharma - Cornerstone Therapeutics - Eli Lilly - Exoxemis - F.Hoffmann-La Roche - Flynn Pharma - Hospira - Incepta Pharmaceuticals - InSite Vision - Insmed Incorporated - Johnson & Johnson - KaloBios Pharmaceuticals - Kyorin Pharmaceutical - Lupin Pharmaceuticals - Lytix Biopharma - Melinta Therapeutics - Mylan - Nektar - Orchid Pharma - Par Pharmaceutical - Paratek Pharmaceuticals - Pernix Therapeutics - PTC Therapeutics - RedHill Biopharma - Sagent Pharmaceuticals - Sanofi - Shionogi - Starpharma - Sun Pharmaceutical - Symbiomix - Takeda Pharma - Tetraphase Pharmaceuticals - Theravance Biopharma - The Medicines Company - Valneva - Wockhardt. For more information visit http://www.researchandmarkets.com/research/nm7f8c/global
TTPH: 4.16 (unch), INSM: 10.93 (-0.14), RDHL: 12.46 (+0.16), LLY: 82.09 (+0.11), BMY: 75.06 (-0.50), PRTK: 12.97 (-0.03), APHB: 1.46 (-0.04), AGN: 248.95 (+1.10), JNJ: 125.15 (+0.26), MRK: 58.36 (-0.20), SGNT: 21.64 (-0.03), PTCT: 5.88 (-0.88), TBPH: 22.84 (+0.25)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 94.98 (-0.79), RIGL: 2.27 (+0.03), OCUL: 4.64 (+0.22), AGN: 248.95 (+1.10), SHPG: 193.60 (+1.31), MRK: 58.36 (-0.20), CLTX: 36.01 (+16.34)
InSite Vision announces unsolicited acquisition proposal from buyer at USD0.25 per share in cash
M2 - Sun Nov 08, 3:01AM CST
InSite Vision (OtherOTC:INSV) said on Monday that it has received an unsolicited proposal for the acquisition of all outstanding shares of its common stock at a price of USD0.25 per share in cash.
QLT (QLTI) Reports Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 11:15AM CDT
QLT Inc. (QLTI) reported a third-quarter 2015 loss of 5 cents per share.
QLTI: 1.38 (-0.02), AMAG: 24.95 (-0.76), ANIK: 51.83 (+0.02)
Ocular (OCUL) Initiates Third Phase III Study on Dextenza
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:25PM CDT
Ocular (OCUL) initiated patient enrolment in the third phase III study on Dextenza for the treatment of post-surgical ocular inflammation and pain.
AGN: 248.95 (+1.10), OCUL: 4.64 (+0.22), NVS: 83.02 (-0.44)
InSite Vision Terminates QLT Deal in Favor of Sun Pharma
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 3:50PM CDT
InSite Vision Inc. (INSV) announced that it has terminated its agreement with QLT Inc. (QLTI).
QLTI: 1.38 (-0.02), GILD: 81.05 (-7.50), REGN: 398.27 (+3.37)
InSite Vision enters into merger agreement with Sun Pharma at USD0.35 per share
M2 - Wed Sep 16, 5:41AM CDT
Ophthalmologic company InSite Vision (OtherOTC:INSV) revealed on Tuesday the launch of a merger agreement with a subsidiary of Sun Pharmaceutical Industries through a tender offer.
QLT Announces Termination of Merger Agreement With InSite Vision
GlobeNewswire - Tue Sep 15, 5:16PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT"
today announced that its agreement to acquire InSite Vision Incorporated (OTCBB:INSV) ("InSite" has been terminated. QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
InSite Vision and Sun Pharma Enter into Merger Agreement
BusinessWire - Tue Sep 15, 3:23PM CDT
--InSite Terminates Merger Agreement with QLT Inc.
QLTI: 1.38 (-0.02)
Eye Infections Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/376x9w/eye_infections) has announced the addition of the "Eye Infections Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report provides an overview of Eye Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Eye Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Alcon - Allergan - Dompe Farmaceutici - InSite Vision - Laboratoires Thea - Merck & Co. - Novartis - SIFI - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/37...infections
AGN: 248.95 (+1.10), MRK: 58.36 (-0.20), VRX.TO: 30.37 (+0.15), NVS: 83.02 (-0.44)
Is Another Amendment of QLT-InSite Vision Deal Coming Up?
Zacks Equity Research - Zacks Investment Research - Tue Sep 08, 3:25PM CDT
InSite Vision Inc. (INSV), which is set to be acquired by QLT Inc. (QLTI), announced that it has received a superior unsolicited offer from a global pharmaceutical company.
QLTI: 1.38 (-0.02), GILD: 81.05 (-7.50), REGN: 398.27 (+3.37)
QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Fri Sep 04, 8:01PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
announces that it has been advised by InSite Vision Incorporated ("InSite" that the board of directors of InSite has determined, in good faith and after consultation with its independent financial and legal advisors, that the second unsolicited offer, as announced in QLT's press release on September 3, 2015, from the multi-national pharmaceutical company (the "Bidder" to acquire all of the issued and outstanding shares of InSite (the "New Proposal" constitutes a "Company Superior Proposal", as defined in the Amended and Restated Agreement and Plan of Merger, dated June 8, 2015, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated on July 16, 2015 and August 26, 2015 (the "Amended and Restated Merger Agreement" . QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a "Company Superior Proposal"
BusinessWire - Fri Sep 04, 4:49PM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that InSite's Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company (the "Bidder"
to acquire all outstanding shares of InSite Vision common stock at $0.35 per share in an all-cash transaction constitutes a "Company Superior Proposal" as defined in InSite's previously announced definitive agreement with QLT Inc. dated as of August 26, 2015 (NASDAQ:QLTI) (TSX:QLT). QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Thu Sep 03, 5:35PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
announces that it has been advised by InSite Vision Incorporated ("InSite" that InSite has received a second unsolicited offer from the multi-national pharmaceutical company which initially made an unsolicited offer, as announced in QLT's press release on August 10, 2015, to acquire all of the issued and outstanding shares of InSite (the "New Proposal" . The New Proposal is only subject to due diligence regarding the recently filed BromSite patent lawsuit. InSite has further advised QLT that the board of directors of InSite, in consultation with its financial and legal advisors, will carefully review all aspects of the New Proposal, and has not changed its recommendation with respect to the proposed merger with QLT pursuant to the Amended and Restated Agreement and Plan of Merger, dated June 8, 2015, by and among InSite, QLT and Isotope Acquisition Corp., as amended and restated on July 16, 2015 and August 26, 2015 (the "Amended and Restated Merger Agreement" . The Amended and Restated Merger Agreement continues in full force and effect. QLTI: 1.38 (-0.02), QLT.TO: 1.80 (unch)
(0)
(0)Scroll down for more posts ▼